Citius Pharmaceuticals Co-Founder and CEO Discusses Recent Acceptance of Biologics License Application for Lymphir for the Treatment of Relapsed/Refractory CTCL

In an interview with Pharm Exec Associate Editor Don Tracy, Leonard Mazur, co-founder and CEO of Citius Pharmaceuticals, discusses the FDA’s recent acceptance of Lymphir’s Biologics License Application and an update on other drug candidates currently in Citius’ pipeline.